MA41794A - Agents thérapeutiques modifiés et compositions associées - Google Patents

Agents thérapeutiques modifiés et compositions associées

Info

Publication number
MA41794A
MA41794A MA041794A MA41794A MA41794A MA 41794 A MA41794 A MA 41794A MA 041794 A MA041794 A MA 041794A MA 41794 A MA41794 A MA 41794A MA 41794 A MA41794 A MA 41794A
Authority
MA
Morocco
Prior art keywords
therapeutic agents
modified therapeutic
associated compositions
compositions
modified
Prior art date
Application number
MA041794A
Other languages
English (en)
Inventor
Avinash Muppidi
Peter G Schultz
Weijun Shen
Original Assignee
The California Institute For Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The California Institute For Biomedical Res filed Critical The California Institute For Biomedical Res
Publication of MA41794A publication Critical patent/MA41794A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
MA041794A 2015-03-18 2016-03-16 Agents thérapeutiques modifiés et compositions associées MA41794A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562134939P 2015-03-18 2015-03-18

Publications (1)

Publication Number Publication Date
MA41794A true MA41794A (fr) 2018-01-23

Family

ID=56919638

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041794A MA41794A (fr) 2015-03-18 2016-03-16 Agents thérapeutiques modifiés et compositions associées

Country Status (9)

Country Link
US (1) US20180207276A1 (fr)
EP (1) EP3270946A2 (fr)
JP (1) JP2018511574A (fr)
KR (1) KR20170125978A (fr)
CN (1) CN107645955A (fr)
AU (1) AU2016233128A1 (fr)
CA (1) CA2978184A1 (fr)
MA (1) MA41794A (fr)
WO (1) WO2016149501A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3310376A4 (fr) * 2015-06-17 2019-01-23 The California Institute for Biomedical Research Agents thérapeutiques modifiés et compositions associées
TW201837051A (zh) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
EP3600439A4 (fr) * 2017-03-22 2021-01-13 The Regents of the University of California Oligonucléotides modifiés et leurs utilisations thérapeutiques
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019085773A1 (fr) * 2017-11-06 2019-05-09 中山大学 Polypeptide agoniste à double cible glp-1r/gcgr analogue d'oxyntomoduline pour le traitement de la fibrose interstitielle pulmonaire idiopathique
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
TW202120536A (zh) 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
EP3819307A1 (fr) 2019-11-07 2021-05-12 CytoKi Pharma ApS Dérivés thérapeutiques de l'interleukine-22
KR102193211B1 (ko) * 2019-11-27 2020-12-18 (주)디앤디파마텍 비오틴 모이어티가 결합된 폴리펩티드 및 이를 포함하는 경구 투여용 약학적 조성물
EP3903806A4 (fr) * 2020-01-20 2022-08-10 Rudacure Corporation Composition pharmaceutique pour le traitement de maladies médiées par l'activité trpv1
CN114478709A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5911997A (en) * 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
BR112013003522B1 (pt) * 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
WO2013007563A1 (fr) * 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Protéines de fusion libérant de la relaxine et leurs utilisations

Also Published As

Publication number Publication date
JP2018511574A (ja) 2018-04-26
CN107645955A (zh) 2018-01-30
US20180207276A1 (en) 2018-07-26
KR20170125978A (ko) 2017-11-15
CA2978184A1 (fr) 2016-09-22
EP3270946A2 (fr) 2018-01-24
AU2016233128A1 (en) 2017-11-09
WO2016149501A2 (fr) 2016-09-22
WO2016149501A3 (fr) 2016-11-24

Similar Documents

Publication Publication Date Title
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
HK1226301A1 (zh) 修飾的治療劑及其組合物
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3529248T3 (da) Farmaceutiske sammensætninger
MA40764A (fr) Agent thérapeutique induisant une cytotoxicité
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3107563T3 (da) Glycomålrettede terapeutiske midler
KR20180084891A (ko) 구조 조성물 및 방법
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
EP3310376A4 (fr) Agents thérapeutiques modifiés et compositions associées
MA39483A (fr) Agents thérapeutiques cibles
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3393478T3 (da) Kombinationsterapi
DK3164117T3 (da) Misbrugssikre formuleringer med øjeblikkelig frigivelse omfattende ikke-cellulose-polysaccharider
DK3408265T3 (da) Terapeutiske forbindelser
MA49905A (fr) Polyesteramines et polyesterquats
DK3240821T3 (da) Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3302478T3 (da) Pac-1 kombinations behandling
DK3129057T3 (da) Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi